Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and six months ended June 30, 2024
Business Overview: Vivos is a medical technology company developing non-surgical oral appliances and therapeutic treatments for obstructive sleep apnea (OSA) and dentofacial abnormalities. The company operates primarily through the "Vivos Integrated Practice" (VIP) program, training dentists to use its proprietary "Vivos Method." In Q2 2024, the company pivoted to a new strategic alliance model, partnering with sleep center operators (e.g., Rebis Health) to distribute treatments directly to patients.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $4,054 | $3,395 | $7,473 | $7,253 |
| Gross Profit | $2,651 | $2,098 | $4,588 | $4,436 |
| Gross Margin | 65% | 62% | 61% | 61% |
| Operating Loss | $(1,936) | $(4,517) | $(5,719) | $(9,521) |
| Net Loss | $(1,930) | $(5,528) | $(5,692) | $(7,231) |
| Cash and Equivalents (End of Period) | $6,903 | $3,942 | $6,903 | $3,942 |
| Accumulated Deficit | $(98,744) | $(86,699) | $(98,744) | $(86,699) |
Liquidity: As of June 30, 2024, the company held $6.9 million in cash. Management states this is insufficient to fund operations for the next 12 months without additional financing.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19% in Q2 2024 ($4.05M) compared to Q2 2023 ($3.40M), driven by a 28% increase in product revenue (appliances and guides) and a 12% increase in service revenue. The six-month revenue increase was modest at 3% ($7.47M vs $7.25M).
- Expense Reduction: Operating expenses decreased significantly. General and Administrative (G&A) expenses dropped 30% in Q2 2024 ($4.12M vs $5.88M) and 27% for the six months, primarily due to reduced professional fees and personnel costs following a reduction in force in 2023.
- Profitability Improvement: The operating loss narrowed substantially to $1.94M in Q2 2024 from $4.52M in Q2 2023. The net loss improved to $1.93M from $5.53M, excluding non-operating items related to warrant liabilities present in 2023 but eliminated in late 2023.
- Capital Structure: The company completed a $7.5 million private placement in June 2024 and a $4.0 million warrant inducement in February 2024, significantly boosting cash reserves and stockholders' equity.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Pivot: Management is shifting focus from solely enrolling dentists (VIPs) to a "Strategic Alliance" model with sleep centers (e.g., Rebis Health) to drive patient volume and revenue sharing.
- Going Concern Warning: The filing explicitly states that current cash levels raise "substantial doubt" regarding the company's ability to continue as a going concern without additional financing. Future funding is expected to come from equity issuances.
- Nasdaq Compliance: The company previously received notice of non-compliance with Nasdaq's $2.5 million stockholders' equity requirement. The June 2024 financing restored compliance, and the Nasdaq Hearings Panel granted continued listing subject to filing this 10-Q.
- Revenue Recognition Adjustments: Service revenue for the six months was impacted by an increase in the estimated "customer life" for VIP contracts (from 23 months in 2023 to 27 months in 2024), which spreads revenue recognition over a longer period, reducing current period revenue despite higher retention.
- Legal Proceedings: Ongoing litigation with Ortho-Tain, Inc. regarding false advertising and trade libel remains pending in the Tenth Circuit.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.9 million cash balance against the stated 12-month funding gap and the timeline for the new strategic alliance to generate positive cash flow.
- Equity Dilution: Assess the impact of the recent $7.5M private placement and outstanding warrants (approx. 9.1 million shares) on future dilution.
- Strategic Alliance Viability: Monitor the performance of the new Rebis Health alliance to determine if it can replace the declining VIP enrollment model as a primary revenue driver.
- Nasdaq Status: Confirm continued compliance with Nasdaq listing rules, specifically the $2.5 million equity requirement, in subsequent filings.
- Revenue Quality: Review the composition of service revenue, noting the impact of "breakage" (accelerated recognition for VIPs who drop out) and the extended amortization periods for new contracts.